<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T19:43:36Z</responseDate><request verb="GetRecord" identifier="oai:digital.lib.washington.edu:1773/20201" metadataPrefix="dim">https://digital.lib.washington.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:digital.lib.washington.edu:1773/20201</identifier><datestamp>2025-01-08T13:45:45Z</datestamp><setSpec>com_1773_4888</setSpec><setSpec>col_1773_4918</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Wald, Anna</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US" authority="1b65f95a-fb53-4887-979f-f8282dbec8d9" confidence="-1">Pollack, Margaret</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2012-08-10T17:10:53Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2013-08-11T11:05:11Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2012-08-10</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted" lang="en_US">2012</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">Pollack_washington_0250O_10091.pdf</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/1773/20201</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">Thesis (Master's)--University of Washington, 2012</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Cytomegalovirus (CMV) surveillance and preemptive therapy (PET) is the most commonly used strategy for CMV disease prevention in hematopoietic cell transplant (HCT) recipients. In 2007, we introduced a CMV prevention strategy for those patients at risk for CMV disease using quantitative PCR surveillance, with treatment thresholds determined by patient risk factors. Patients (N=384) received PET either at a plasma viral load of ≥500 copies/ml, at ≥100 copies/ml if receiving ≥ 1 mg/kg of prednisone or anti-T cell therapies, or if a ≥ 5-fold viral load increase from baseline was detected. Compared to patients prior to 2007 undergoing antigenemia-based surveillance (n=690) with PET initiated for any positive level, the risk-adapted PCR based strategy resulted in similar use of antiviral agents, and similar risks of CMV disease, toxicity and non-relapse mortality (NRM) in multivariable models. The cumulative incidence of CMV disease by day 100 was 5.2% in the PCR group compared to 5.8% in the antigenemia group (1 year: 9.1% PCR vs 9.6% antigenemia). Breakthrough CMV disease in the PCR group was predominantly in the gastrointestinal (GI) tract (16/20 cases, 80%). However, unlike CMV pneumonia, CMV GI disease was not associated with increased NRM (adjusted hazard ratio 1.13, P=0.8 [GI disease] vs. 8.41, P&lt;0.001 [pneumonia]).  Additionally, in this contemporary cohort CMV seropositivity in the donor or recipient was not associated with NRM at 1 year. Thus, the transition to a PET strategy based on CMV viral load and host risk factors successfully prevented CMV disease without increasing the proportion of patients receiving PET and attributable toxicity. Breakthrough disease in PCR-based PET occurs at a low incidence and presents primarily as GI disease which is more likely to be responsive to antiviral therapy.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype" lang="en_US">application/pdf</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en_US</dim:field>
   <dim:field mdschema="dc" element="rights" lang="en_US">Copyright is held by the individual authors.</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">cytomegalovirus; hematopoietic cell transplant</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other" lang="en_US">Medicine</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other" lang="en_US">Epidemiology</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of Cytomegalovirus disease after hematopoietic cell transplantation</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="terms" lang="en_US">Restrict to UW for 1 year -- then make Open Access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>